EFFICACY, SAFETY, AND TOLERABILITY OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) TREATMENT FOR HIV/HCV CO-INFECTED PARTICIPANTS WHO SWITCH TO ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (E/C/F/TAF) OR EMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE (F/R/TAF) PRIOR TO LDV/SOF HCV TREATMENT: